Last reviewed · How we verify

NCT05014815

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Completed Phase 2 Results posted Last updated 16 September 2025
What this trial tests

Phase 2 trial testing Ociperlimab in Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC) in 272 participants. Completed in 4 September 2024.

Timeline
16 November 2021
Primary endpoint
4 September 2024
4 September 2024

Quick facts

Lead sponsorBeiGene
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment272
Start date16 November 2021
Primary completion4 September 2024
Estimated completion4 September 2024
Sites64 locations across France, Greece, Austria, South Korea, Australia, China, United States, Spain

Drugs / interventions tested

Conditions studied

Sponsor

BeiGene — full company profile →

Who can join

18 and older, any sex, with Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC) or Nonsmall Cell Lung Cancer, Stage IIIB. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Progression-free Survival (PFS) Primary · From randomization up to the final efficacy analysis data cut-off date of 04 September 2024; Up to 33 months

PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

GroupValue95% CI
Arm A (O+T+C)8.26.2 – 10.6
Arm B (P+T+C)8.16.0 – 10.2
Objective Response Rate (ORR) Secondary · From randomization up to the final efficacy analysis data cut-off date of 04 September 2024; Up to 33 months

Objective response rate is defined as the percentage of participants who had a confirmed complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments. CR is defined as the disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

GroupValue95% CI
Arm A (O+T+C)41.933.5 – 50.7
Arm B (P+T+C)47.839.2 – 56.5
Duration of Response (DOR) Secondary · From randomization up to the final efficacy analysis data cut-off date of 04 September 2024; Up to 33 months

DOR was defined as the time from the first documented objective response to documented radiological disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Progressive disease is captured as at least a 20% increase in the sum of diameters of target lesions, using the smallest sum on study as the reference (including the baseline sum if it was the smallest). In addition to the 20% relative increase, the sum also had to show an absolute increase of at least 5 mm.

GroupValue95% CI
Arm A (O+T+C)10.48.0 – 17.7
Arm B (P+T+C)11.28.1 – 13.9
Overall Survival (OS) Secondary · From randomization up to the final efficacy analysis data cut-off date of 04 September 2024; Up to 33 months

OS was defined as the time from randomization to the documented date of death for participants who died on or before the clinical cutoff date. Median OS was calculated using the Kaplan-Meier method. Data for participants who were alive at the clinical cutoff date were censored at their last known alive date, defined as either the clinical cutoff date for those still on treatment or the most recent available date confirming they were alive, whichever occurred first.

GroupValue95% CI
Arm A (O+T+C)20.614.4 – NA
Arm B (P+T+C)19.415.4 – 23.1
Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Secondary · From first dose of study drug to 30 days after last dose, up to the study completion date cut-off date of 04 September 2024 (up to 32.4 months)

The number of participants who experienced TEAEs and SAEs was reported. An adverse event refers to any unintended or unfavorable sign, symptom, or condition (including abnormal lab results) that occurs during the study, regardless of whether it is linked to the study drug. Investigators evaluated the severity of each adverse event according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.

Number of participants with any TEAEs
GroupValue95% CI
Arm A (O+T+C)134
Arm B (P+T+C)135
Number of participants with SAEs
GroupValue95% CI
Arm A (O+T+C)63
Arm B (P+T+C)74

Adverse events — posted to ClinicalTrials.gov

Time frame: All-cause mortality is reported from randomization up to study completion date cut-off date of 04 September 2024, up to 33 months. AEs are reported from first dose of study drug to 30 days after last dose, up to study completion date of 04 September 2024, up to 32.4 months.. Reporting threshold: 3%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Arm A (O+T+C)
Serious: 63/135 (47%)
Deaths: 63/136
Arm B (P+T+C)
Serious: 74/136 (54%)
Deaths: 70/136

Serious adverse events (121 terms)

ReactionSystemArm A (O+T+C)Arm B (P+T+C)
PneumoniaInfections and infestations
AnaemiaBlood and lymphatic system disorders
PyrexiaGeneral disorders
Neutrophil count decreasedInvestigations
Platelet count decreasedInvestigations
White blood cell count decreasedInvestigations
Respiratory failureRespiratory, thoracic and mediastinal disorders
Febrile neutropeniaBlood and lymphatic system disorders
COVID-19 pneumoniaInfections and infestations
PneumonitisRespiratory, thoracic and mediastinal disorders
Pulmonary embolismRespiratory, thoracic and mediastinal disorders
LeukopeniaBlood and lymphatic system disorders
Immune-mediated enterocolitisGastrointestinal disorders
DyspnoeaRespiratory, thoracic and mediastinal disorders
HaemoptysisRespiratory, thoracic and mediastinal disorders
NeutropeniaBlood and lymphatic system disorders
ThrombocytopeniaBlood and lymphatic system disorders
Immune-mediated myocarditisCardiac disorders
DiarrhoeaGastrointestinal disorders
NauseaGastrointestinal disorders
DeathGeneral disorders
InfluenzaInfections and infestations
SepsisInfections and infestations
Urinary tract infectionInfections and infestations
Blood creatinine increasedInvestigations
Other adverse events (81 terms — click to expand)

ReactionSystemArm A (O+T+C)Arm B (P+T+C)
AnaemiaBlood and lymphatic system disorders
White blood cell count decreasedInvestigations
Neutrophil count decreasedInvestigations
NauseaGastrointestinal disorders
Platelet count decreasedInvestigations
ConstipationGastrointestinal disorders
Alanine aminotransferase increasedInvestigations
Decreased appetiteMetabolism and nutrition disorders
RashSkin and subcutaneous tissue disorders
Aspartate aminotransferase increasedInvestigations
VomitingGastrointestinal disorders
HypoalbuminaemiaMetabolism and nutrition disorders
PruritusSkin and subcutaneous tissue disorders
FatigueGeneral disorders
AlopeciaSkin and subcutaneous tissue disorders
DiarrhoeaGastrointestinal disorders
CoughRespiratory, thoracic and mediastinal disorders
HypokalaemiaMetabolism and nutrition disorders
Blood creatinine increasedInvestigations
Lymphocyte count decreasedInvestigations
HypothyroidismEndocrine disorders
HyponatraemiaMetabolism and nutrition disorders
PyrexiaGeneral disorders
COVID-19Infections and infestations
Oedema peripheralGeneral disorders
AstheniaGeneral disorders
Weight decreasedInvestigations
Weight increasedInvestigations
SARS-CoV-2 test positiveInvestigations
HyperglycaemiaMetabolism and nutrition disorders
InsomniaPsychiatric disorders
StomatitisGastrointestinal disorders
PneumoniaInfections and infestations
Blood bilirubin increasedInvestigations
DyspnoeaRespiratory, thoracic and mediastinal disorders
LeukopeniaBlood and lymphatic system disorders
ThrombocytopeniaBlood and lymphatic system disorders
Abdominal painGastrointestinal disorders
Gamma-glutamyltransferase increasedInvestigations
NeutropeniaBlood and lymphatic system disorders

Most-reported serious reactions: Pneumonia, Anaemia, Pyrexia, Neutrophil count decreased, Platelet count decreased, White blood cell count decreased, Respiratory failure, Febrile neutropenia.

Data from ClinicalTrials.gov NCT05014815 adverse events section.

Sponsor's own description

This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that was locally advanced, could not be removed by surgery, or had spread to other parts of the body.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
    Cai L, Li Y, Tan J, Xu L, et al · · 2023 · cited 232× · PMID 37670328 · DOI 10.1186/s13045-023-01499-1
  2. Exploiting innate immunity for cancer immunotherapy.
    Yi M, Li T, Niu M, Mei Q, et al · · 2023 · cited 151× · PMID 38008741 · DOI 10.1186/s12943-023-01885-w
  3. Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.
    Chu X, Tian W, Wang Z, Zhang J, et al · · 2023 · cited 147× · PMID 37291608 · DOI 10.1186/s12943-023-01800-3
  4. Anti-TIGIT therapies for solid tumors: a systematic review.
    Rousseau A, Parisi C, Barlesi F. · · 2023 · cited 111× · PMID 36933320 · DOI 10.1016/j.esmoop.2023.101184
  5. Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
    Zhang P, Liu X, Gu Z, Jiang Z, et al · · 2024 · cited 69× · PMID 38229100 · DOI 10.1186/s40364-023-00543-z
  6. Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer.
    Liu X, Xi X, Xu S, Chu H, et al · · 2024 · cited 40× · PMID 39726592 · DOI 10.3389/fimmu.2024.1507501
  7. Update in TIGIT Immune-Checkpoint Role in Cancer.
    Annese T, Tamma R, Ribatti D. · · 2022 · cited 40× · PMID 35656508 · DOI 10.3389/fonc.2022.871085
  8. Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.
    Li MSC, Mok KKS, Mok TSK. · · 2023 · cited 37× · PMID 37675321 · DOI 10.21037/atm-22-4444

Verify or expand the search:

Other trials of Ociperlimab

Trials testing the same drug.

Other BeiGene trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05014815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing